Table 1.
Patient characteristics by genetic and molecular groups
| Total (%) | KRAS wild-type (%) | KRAS mutated (%) | p * | |
|---|---|---|---|---|
| No. of patients | 78 | 51 (65.4) | 27 (34.6) | |
| Age at surgery | 0.614 | |||
| <60 | 26 (33.3) | 18 (35.3) | 8 (29.6) | |
| ≥60 | 52 (66.7) | 33 (64.7) | 19 (70.4) | |
| Sex | 0.555 | |||
| Male | 44 (56.4) | 30 (58.8) | 14 (51.9) | |
| Female | 34 (43.6) | 21 (41.2) | 13 (48.1) | |
| Stage | 0.022† | |||
| Early stage (T1–4 N0 M0) | 25 (32.1) | 21 (41.2) | 4 (14.8) | |
| Late stage (anyT N1-2 M0) | 53 (67.9) | 30 (58.8) | 23 (85.2) | |
| Tumor differentiation | 0.167 | |||
| Well/Moderate | 43 (55.1) | 31 (60.8) | 12 (44.4) | |
| Poor | 35 (44.9) | 20 (39.2) | 15 (55.6) | |
| Extent of resection | 0.086† | |||
| R0 | 68 (87.2) | 47 (92.2) | 21 (77.8) | |
| R1/R2 | 10 (12.8) | 4 (7.8) | 6 (22.2) | |
| Chemotherapy/radiotherapy | 0.241 | |||
| No | 27 (34.6) | 20 (39.2) | 7 (25.9) | |
| Yes | 51 (65.4) | 31 (60.8) | 20 (74.1) | |
| MSI status | 0.390† | |||
| MSS | 61 (78.2) | 38 (74.5) | 23 (85.2) | |
| MSI | 17 (21.8) | 13 (25.5) | 4 (14.8) |
*
KRAS wild-type vs. KRAS mutated, χ2 test unless indicated otherwise;
†
Fisher’s exact test; MSS, microsatellite stable; MSI, microsatellite instability